IBC's Drug Discovery Technology - Europe 2001. 23-26 April 2001, Stuttgart, Germany.
Specific sectors within the pharmaceutical industry are rapidly changing in response to technological advances. Genomics, high-throughput automated chemistry, high-throughput screening (HTS), ADME/Tox screening and informatics, provide new opportunities, but also create new bottlenecks. In addition, the selection and validation of biological targets, the proper design of compound libraries, data and knowledge management, and as the last and crucial step, the proof of therapeutic relevance by clinical trials, generates an enormous financial load on biotechnology and pharmaceutical companies. In the future, drug development costs might be reduced due to an ongoing pressure for shorter development cycles of new drugs. IBC's Drug Discovery Technology Europe 2001 conference addressed many aspects relevant to drug discovery technologies, and, along with its US partner conference, provides an annual meeting place for researchers and company executives to interact and exchange ideas.
Kubinyi
H
H
Combinatorial Chemistry & Molecular Modelling, BASF AG, ZHF/G - A30, D-67056 Ludwigshafen, Germany. hugo.kubinyi@basf-ag.de